Welcome to our dedicated page for Alvotech news (Ticker: ALVO), a resource for investors and traders seeking the latest updates and insights on Alvotech stock.
Alvotech (NASDAQ: ALVO) is a biotechnology company dedicated exclusively to biosimilars, and its news flow reflects the progress of a global biosimilar platform. Company updates frequently cover regulatory milestones, such as marketing authorizations in the European Economic Area, the United Kingdom and Japan for products referencing Prolia and Xgeva (denosumab), Simponi (golimumab) and Eylea (aflibercept). Press releases also highlight clinical and regulatory developments for new candidates, including submissions to agencies like the European Medicines Agency and the U.S. Food and Drug Administration.
Investors following ALVO news can expect regular announcements on product approvals, pipeline progress and legal or regulatory outcomes. Recent communications have described European Commission approval of AVT03, a biosimilar to Prolia and Xgeva, positive opinions from EMA committees for AVT03 and AVT05, and a settlement and license agreement enabling a future U.S. launch of AVT06, a proposed biosimilar to Eylea, subject to FDA approval. Other items include court decisions related to manufacturing activities for AVT06 and updates on applications for additional candidates such as AVT23.
Alvotech’s news flow also includes capital markets and financing transactions, such as senior unsecured convertible bond offerings and a senior term loan facility, which the company states are intended to support its research and development pipeline, manufacturing capacity and global product launches. Earnings-related press releases and business updates provide guidance ranges for revenues and adjusted EBITDA, along with commentary on order books, launch timing and investment programs.
Corporate governance and leadership changes are another recurring theme. For example, Alvotech has announced a planned CEO succession in which the founder will remain as Executive Chairman while a new Chief Executive Officer takes over day-to-day leadership. For users tracking ALVO, this news page offers a centralized view of regulatory, financial and strategic developments affecting the company’s biosimilar portfolio and global partnerships.
Alvotech (NASDAQ: ALVO), a global biotech firm specializing in biosimilar medicines, has issued 22,073,578 new ordinary shares to holders of subordinated convertible bonds. These bonds, originally issued on November 16, 2022, and December 20, 2022, mature on December 20, 2025. The shares were exchanged at a fixed price of $10.00 per share. Most bondholders converting to shares are existing shareholders. Post-conversion, Alvotech's total issued shares are 324,801,040, with 301,944,470 outstanding shares. The new shares will be delivered within seven business days.
Alvotech (NASDAQ: ALVO) announced record preliminary financial results for Q2 2024, highlighting significant growth in revenues and EBITDA. The company reported preliminary total revenues between $196 - $201 million for the second quarter and $233 - $238 million for the first six months, marking a tenfold increase year-over-year. Product revenues from biosimilars to Humira and Stelara reached $51 - $54 million for Q2 and $63 - $66 million for the first half, representing a 180% increase. Preliminary milestone revenues are $145 - $147 million for Q2 and $169 - $171 million for H1 2024. The company achieved a record preliminary adjusted EBITDA of $98 - $103 million for Q2 and $60 - $65 million for H1, reversing a loss of ($178) million in the same period of 2023. CEO Robert Wessman highlighted the role of debt refinancing in achieving these results and driving future growth.
Alvotech (NASDAQ: ALVO), a global biotech firm specializing in biosimilar medicines, announced that the majority of its subordinated convertible bonds will be converted into ordinary shares on July 1, 2024. The bonds, issued on November 16 and December 20, 2022, will mature on December 20, 2025. Conversion will occur at a fixed price of $10.00 per share. Approximately 22.1 million new shares are expected to be issued based on current exchange rates. The conversion involves two tranches: ISK-denominated bonds valued at ISK 25.5 billion (~$183 million), converting into 18.3 million shares, and USD-denominated bonds valued at $37.98 million, converting into 3.8 million shares. An additional $116.68 million in USD-denominated bonds remains unconverted.
Alvotech (NASDAQ: ALVO) and Advanz Pharma have signed a commercialization agreement for Alvotech's proposed biosimilar to Eylea® (aflibercept) in Europe. The biosimilars, AVT06 (low dose) and AVT29 (high dose), target eye disorders like wet AMD and diabetic retinopathy, with Eylea® sales in Europe reported at $2.9 billion in 2023. Alvotech will handle development and supply, while Advanz Pharma will manage registration and commercialization, with exclusive rights in Europe except for semi-exclusive rights in Germany and France. The agreement includes upfront and milestone payments to Alvotech. This partnership expands their collaboration to seven biosimilar candidates. Recent studies showed AVT06 met its primary endpoint, proving therapeutic equivalence to Eylea®.
Alvotech and STADA announced an expanded strategic alliance to market Alvotech’s biosimilar AVT03, referencing Prolia®/Xgeva® (denosumab), in Europe, including Switzerland and the UK, as well as selected markets in Central Asia and the Middle East. This partnership builds on their existing collaboration for biosimilars to Humira® and Stelara®. Alvotech will develop and manufacture AVT03, while STADA will handle marketing upon regulatory approval. Additionally, Alvotech regains commercial rights to its biosimilar AVT06, referencing Eylea® (aflibercept). The expansion aims to offer cost-effective biosimilars to patients, particularly for osteoporosis and cancer-related bone loss.
Alvotech (NASDAQ: ALVO), a global biotech firm specializing in biosimilars, has secured a strategic refinancing deal led by GoldenTree Asset Management and other institutional investors. The agreement includes a senior secured first lien term loan facility up to $965 million, split into two tranches: a $900 million term loan with an interest rate of SOFR plus 6.5% per annum, and an optional $65 million term loan with an interest rate of SOFR plus 10.5% per annum. The facility matures in June 2029 and is set to be funded in July 2024. Proceeds will refinance existing debt maturing in 2025 and support working capital for upcoming product launches. Joel Morales, CFO, emphasized the facility's role in bolstering financial flexibility and sustaining long-term growth.
Alvotech (NASDAQ: ALVO), a global biotech firm, announced its participation in the Jefferies Healthcare Conference in New York from June 5-6, 2024. The company will present and host investor and business meetings during the event. Chief Business Officer Anil Okay will give a presentation on June 6, 2024, at 1:00 pm EDT (17:00 GMT). An audio webcast of the presentation will be accessible live and on-demand on Alvotech’s investor website. Interested parties can register to listen to the live webcast or access the recorded version for up to 90 days.
Alvotech announced its Q1 2024 financial results, reporting a revenue increase to $37 million, up from $16 million in Q1 2023. Gross margins also rose to $17 million. The company has raised its revenue guidance for 2024 to a range of $400-$500 million. Notable achievements include FDA approval for AVT04, a biosimilar to Stelara, and new commercialization agreements for biosimilars to Humira, Prolia, and Xgeva in the U.S. and Europe. Despite a net loss of $218.7 million, compared to $276.2 million last year, Alvotech’s business development continues strong with multiple strategic partnerships and positive clinical results.
Alvotech and Dr. Reddy's have entered a collaboration to commercialize AVT03, a biosimilar to Prolia® and Xgeva® (denosumab), in the US, Europe, and the UK. Dr. Reddy's will have exclusive commercialization rights in the US and semi-exclusive rights in Europe and the UK. Alvotech will handle the development and manufacturing of AVT03. The agreement includes upfront, milestone, and sales-based payments to Alvotech. Erez Israeli, CEO of Dr. Reddy's, emphasized the strategic importance of this collaboration in expanding their biosimilar portfolio. Robert Wessman, Chairman and CEO of Alvotech, highlighted the partnership's potential to improve global access to affordable biologic medications.
Genentech's Inavolisib has received Breakthrough Therapy Designation from the FDA for treating advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation. This designation is expected to expedite the development and review process, potentially bringing the treatment to market faster. Alvotech announced participation in the upcoming BofA Securities Healthcare Conference 2024 on May 14-15 in Las Vegas, where its management team will meet with investors.